Development of next generation drugs for chronic myeloid leukaemia [ 2014 - 2016 ]

Research Grant

Researchers: Prof David Craik (Principal investigator) ,  Dr Quentin Kaas

Brief description Chronic myeloid leukaemia (CML) is one of the four most common types of leukaemia. With current therapies, 15–20% of patients newly diagnosed for CML will die in the next five years, and it is therefore vitally important to discover new treatments. The aim of this project is to develop a new generation of drugs to treat CML based on new approaches (i.e., different type of molecules and different binding site) that can combat the resistance acquired to the current treatments.

Funding Amount $AUD 632,726.45

Funding Scheme Project Grants

Notes Standard Project Grant